Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 3655

Next Previous
X
Search
Drug Profile

MK 3655

Alternative Names: MK-3655; NGM-313

Latest Information Update: 20 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NGM Biopharmaceuticals
  • Developer Merck & Co; NGM Biopharmaceuticals
  • Class Antihyperglycaemics; Hepatoprotectants; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action KLB protein stimulants; Type 1 fibroblast growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Non-alcoholic fatty liver disease; Obesity

Most Recent Events

  • 20 Mar 2023 Discontinued - Phase-I for Non-alcoholic fatty liver disease in USA (SC) (NGM Biopharmaceuticals pipeline, March 2023)
  • 20 Mar 2023 Discontinued - Phase-I for Obesity (In volunteers) in Australia (SC) (NGM Biopharmaceuticals pipeline, March 2023)
  • 09 Jan 2023 Merck Sharp & Dohme terminates a phase IIb trial in Non-alcoholic steatohepatitis in USA, Taiwan, France, Israel, Germany, South Korea, Japan, Russia, Italy, Sweden, Argentina, Australia, Canada, Chile, China, Hong Kong, Mexico, New Zealand, Puerto Rico, Spain, Turkey (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top